Danaher unit Cepheid wins approval of point-of-care hepatitis C test
2024-06-27
designer491/iStock via Getty Images The U.S. FDA has granted marketing authorization to the Xpert HCV test and GeneXpert Xpress System, the first-ever point-of-care test for hepatitis C, from Danaher (NYSE:DHR) subsidiary Cepheid. The test can be performed in places such as doctors’ offices, emergency departments, and urgent care clinics. TheContinue Reading